Finding out you carry an MTHFR variant can feel alarming, especially if you've been reading online forums where it's blamed for everything from fatigue to autoimmune disease. The reality is more nuanced: MTHFR variants are extremely common, most people with them live completely normal lives, and what you actually need to do depends on your specific genotype, your lab values, and your personal health history.
This article covers what the MTHFR gene does, what the two main variants mean in practical terms, when they actually matter clinically, and what interventions have real evidence behind them.
What MTHFR Does — and Why It Matters
MTHFR (methylenetetrahydrofolate reductase) is an enzyme that converts dietary folate into 5-methyltetrahydrofolate (5-MTHF), the active form your body actually uses. This conversion is the rate-limiting step in the folate cycle, which feeds directly into a process called methylation.
Methylation is a biochemical reaction where a methyl group (CH₃) gets transferred from one molecule to another. It happens billions of times per second across your body and is involved in:
- DNA synthesis and repair
- Gene expression (epigenetics)
- Neurotransmitter production (dopamine, serotonin, epinephrine)
- Detoxification pathways
- Processing of homocysteine — an amino acid that becomes harmful at high concentrations
When MTHFR function is reduced, less 5-MTHF is produced. This slows the conversion of homocysteine back into methionine, causing homocysteine to accumulate. Elevated homocysteine — called hyperhomocysteinemia — is the primary clinical concern with MTHFR variants.
The Two Variants: C677T and A1298C
Nearly all clinically significant MTHFR discussion centers on two single nucleotide polymorphisms (SNPs):
C677T (rs1801133) — a cytosine-to-thymine substitution at position 677. This is the more functionally impactful variant:
- Heterozygous (CT): enzyme activity reduced by approximately 35% compared to wild type
- Homozygous (TT): enzyme activity reduced by approximately 70%
The TT genotype is the one that consistently elevates plasma homocysteine in the absence of adequate folate intake. Prevalence varies significantly by ancestry — roughly 10-15% of people of European descent carry the TT genotype, while rates are higher in some Southern European and Mexican-American populations and lower in populations of African descent.
A1298C (rs1801131) — an adenine-to-cytosine substitution at position 1298. This variant has a smaller effect on enzyme activity in isolation. Heterozygous A1298C alone typically does not raise homocysteine significantly. However, compound heterozygosity — carrying one copy of C677T and one copy of A1298C — produces an intermediate effect similar to heterozygous C677T.
The combination that carries the most practical weight is homozygous C677T (TT genotype). If you're heterozygous for either variant alone and your homocysteine is normal, your MTHFR status likely requires no intervention.
When MTHFR Actually Causes Problems
MTHFR variants don't cause disease on their own. They interact with dietary folate status to determine whether homocysteine rises. In populations with adequate folate intake — or in countries with mandatory folic acid fortification of grain products — the clinical impact of MTHFR variants is substantially blunted.
The situations where MTHFR variants are most clinically relevant:
Cardiovascular risk. A 2002 meta-analysis in JAMA pooling data from 30 prospective studies found that homocysteine levels approximately 25% above average were associated with an 11% higher risk of ischemic heart disease and 19% higher risk of stroke. The association is modest compared to major risk factors like smoking or hypertension, but real. Whether lowering homocysteine through B vitamins actually reduces cardiovascular events (as opposed to just lowering the number) has been debated — several large trials showed reduction in homocysteine without proportional cardiovascular benefit.
Neural tube defects in pregnancy. Folate deficiency is a well-established cause of neural tube defects (NTDs) like spina bifida. Women with homozygous C677T have approximately 2-3x higher NTD risk if folate status is inadequate. This is the clearest clinical intervention point — folate supplementation before and during early pregnancy is recommended regardless of MTHFR status, but women with TT genotype need to pay particular attention to adequate folate intake.
Psychiatric and neurological effects. Some evidence links elevated homocysteine with cognitive decline and depression, though causality is difficult to establish. Low folate and elevated homocysteine both associate with depression in observational studies.
Recurrent pregnancy loss. The evidence for MTHFR as an independent risk factor for miscarriage is weak and inconsistent. Several meta-analyses have not confirmed a clinically meaningful association beyond what homocysteine explains.
What to Do: Practical Steps With Evidence
If you have an MTHFR variant — especially homozygous C677T — here's what the evidence actually supports:
Get your homocysteine tested. This is the most important first step. Your MTHFR genotype tells you about enzyme capacity; your plasma homocysteine tells you whether that reduced capacity is actually causing a problem. Optimal fasting homocysteine is generally considered below 10 µmol/L. Levels above 15 µmol/L are associated with increased cardiovascular risk. Many people with TT genotypes have normal homocysteine because their diet is adequate.
Use methylfolate, not just folic acid. Folic acid is the synthetic form used in most supplements and food fortification. It requires conversion to 5-MTHF by MTHFR — which is exactly the enzyme that's partially impaired. If you have a significant MTHFR variant, supplementing with 5-MTHF (methylfolate) bypasses this bottleneck. Common doses studied range from 400 mcg to 5 mg of methylfolate daily. A 2011 study in the American Journal of Clinical Nutrition confirmed that C677T TT individuals showed blunted response to standard folic acid doses.
Ensure adequate B12. Vitamin B12 (cobalamin) is a cofactor in the methionine synthase reaction that converts homocysteine to methionine. Low B12 raises homocysteine independently of MTHFR status. The active form methylcobalamin is often recommended for people with MTHFR variants, though evidence that it's superior to cyanocobalamin in this context is limited.
Don't neglect B6. Vitamin B6 supports the transsulfuration pathway, an alternative route for homocysteine clearance. B6 deficiency raises homocysteine. Adequate B6 intake from diet or supplements (the RDA is 1.3-1.7 mg/day for adults) covers this.
Eat folate-rich foods. Leafy greens (spinach, arugula, romaine), legumes (lentils, black beans, chickpeas), asparagus, broccoli, and avocado are all high in natural food folate. Unlike folic acid, food folate includes naturally occurring 5-MTHF and other reduced folate forms. A diet with regular servings of these foods makes a substantial difference in homocysteine levels.
Reduce alcohol intake. Alcohol impairs folate absorption and metabolism, which is particularly relevant for people with MTHFR variants.
If you want to understand how your MTHFR genotype interacts with other variants in your data — including how your B12 processing and methylation pathways look together — Ask My DNA lets you ask these specific questions directly from your genetic file.
The COMT Interaction: Why More Methyl Isn't Always Better
Here's where individual variation matters significantly. Some people with MTHFR variants also carry a slow-activity COMT variant.
COMT (catechol-O-methyltransferase) uses methyl groups to break down catecholamines — dopamine, epinephrine, norepinephrine — and estrogens. The Val158Met variant (rs4680) reduces COMT activity significantly. People who are homozygous for the Met allele (Met/Met) clear dopamine and estrogens more slowly.
If you have both a slow MTHFR (producing less methyl donor) and a slow COMT (using fewer methyl groups), you might actually have near-normal net methylation balance. Conversely, if someone with slow COMT aggressively supplements with methylfolate and methylcobalamin, they can overshoot — producing excess methyl groups that drive anxiety, irritability, and difficulty sleeping.
This is one area where one-size-fits-all "MTHFR protocols" can backfire. A person with MTHFR TT and COMT Met/Met genuinely needs different considerations than a person with MTHFR TT and fast-activity COMT (Val/Val).
Other genes worth knowing in this context:
- FOLH1 — affects how efficiently dietary folate is absorbed in the gut
- MTR and MTRR — enzymes in the methionine cycle; variants can affect how well you use B12 in methylation
- CBS (cystathionine beta-synthase) — fast-activity variants accelerate homocysteine clearance through transsulfuration, which can partially compensate for slower MTHFR
What Not to Do
The MTHFR wellness industry has generated a significant amount of pseudoscience. Here's what the evidence doesn't support:
Don't assume MTHFR explains your symptoms. Fatigue, brain fog, anxiety, pain — these symptoms have many causes. MTHFR variants are not a satisfying explanation for complex, multisystem symptoms unless you also have documented elevated homocysteine or documented folate deficiency.
Don't take high-dose methylfolate without checking COMT and your baseline. Doses above 1 mg of methylfolate can cause side effects in some people — anxiety, irritability, insomnia — especially in those with slow COMT. Starting low (400 mcg) and titrating is more sensible than jumping to 5 mg.
Don't avoid all folic acid categorically. For most heterozygous carriers with normal homocysteine, folic acid fortified foods are not a problem. The issue with unmetabolized folic acid (UMFA) accumulating in blood is a real biochemical phenomenon but its clinical significance at standard dietary exposure levels is not established.
Don't order "MTHFR panels" from direct-to-consumer testing companies that include 20+ MTHFR variants. Only C677T and A1298C have meaningful evidence. The others are largely noise in the context of clinical decision-making.
MTHFR and Pregnancy: What You Need to Know
For women who are pregnant or planning to become pregnant, MTHFR status is particularly worth understanding. The strongest evidence:
- Homozygous C677T (TT) women have elevated risk of NTD-affected pregnancies, driven by folate insufficiency
- The MRC Vitamin Study (Lancet, 1991) established that folic acid supplementation reduces NTD risk by approximately 70%
- Current guidelines recommend 400 mcg folic acid daily for all women of reproductive age, and 4 mg daily for those with prior NTD-affected pregnancies
- For TT women, many clinicians recommend supplementing with methylfolate instead of or in addition to folic acid, though randomized trial data on this specific point are limited
Plasma homocysteine tends to fall naturally during pregnancy due to hemodilution and increased folate demand. Testing homocysteine during pregnancy should be interpreted with this context.
Frequently Asked Questions
Should everyone with MTHFR take methylfolate?
No. The decision depends on your specific genotype, your plasma homocysteine level, your dietary folate intake, and your personal health context. People who are heterozygous for A1298C alone with normal homocysteine likely need nothing beyond a folate-rich diet. Homozygous C677T individuals with elevated homocysteine have a clearer indication for methylfolate supplementation. Talk to a physician who can order relevant labs before adding supplements.
Is MTHFR the reason I feel tired all the time?
Probably not by itself. Fatigue is one of the most common symptoms in medicine and has dozens of causes. MTHFR variants can contribute to fatigue if they're causing documented folate deficiency or significantly elevated homocysteine — but these need to be confirmed with lab tests, not assumed from the genotype alone. Iron deficiency, thyroid dysfunction, sleep quality, and B12 deficiency are all far more common causes of fatigue.
What's the difference between folic acid and methylfolate?
Folic acid is synthetic folate that requires enzymatic conversion (by MTHFR among other enzymes) to become biologically active 5-MTHF. Methylfolate (5-MTHF or 5-methyltetrahydrofolate) is the active form that can be directly used without conversion. For people with significantly reduced MTHFR activity, methylfolate supplementation bypasses the conversion step. Products like Metafolin and Quatrefolic are methylfolate forms available in supplements.
Does MTHFR increase my cancer risk?
The relationship between MTHFR and cancer is complex and varies by cancer type. Some studies suggest the C677T TT genotype is associated with reduced risk of colorectal cancer (possibly because reduced folate availability slows rapidly dividing cells), while other associations with breast or other cancers have been inconsistent across populations. MTHFR is not a high-impact cancer risk gene in the way that BRCA1/2 are. The primary clinical focus remains cardiovascular disease and pregnancy outcomes.
Can I test for MTHFR without a doctor?
Yes — consumer DNA testing services (23andMe, AncestryDNA) report C677T and A1298C in their raw data, and Ask My DNA lets you query your raw genome file for these specific variants and ask follow-up questions about what they mean for your situation. However, interpreting genotype results in the context of your personal health still benefits from physician input, particularly if you're considering supplementation changes or have symptoms you're trying to explain.
Educational Content Disclaimer
This article provides educational information about genetic variants and is not intended as medical advice. Always consult qualified healthcare providers for personalized medical guidance. Genetic information should be interpreted alongside medical history and professional assessment.